Kura Oncology (KURA)
(Delayed Data from NSDQ)
$18.97 USD
-0.15 (-0.78%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $18.95 -0.02 (-0.11%) 6:30 PM ET
4-Sell of 5 4
D Value F Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Kura Oncology, Inc. [KURA]
Reports for Purchase
Showing records 201 - 220 ( 263 total )
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
AITL Update at ASH; FDA Gives Nod to Registration-Directed Ph 2 Design
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Results; AIM-HN Pushes Forward and ASH Bringing Important Heme Updates
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Update for Tipifarnib in AITL Patients Ahead at ASH
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Ph 2 HNSCC Update Points to High Likelihood of Success for AIM-HN Pivotal Study
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Compelling RUN-HN Update Strengthens Confidence in Pivotal AIM-HN Outcome
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
KO-539 Hits the Clinic Ready to Make a Splash
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Tipifarnib Market Potential Continues to Broaden
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Positive Ph 2 Data for Tipifarnib in HRAS-Mutant Urothelial Cancer IST Study
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Tipifarnib Potential Continues to Broaden; Pipeline Progresses
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Results; Building the Depth and Breadth Story for Tipifarnib; Adjusting target to $29
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE -EHA Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
EHA Presentations: Positive Ph 2 data for AITL and CXCL12+ Cohorts
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
EHA Presentations: Positive Ph 2 data for AITL and CXCL12+ Cohorts
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Precision Medicine Thesis Takes Big Leap Forward; Looking Ahead to Regulatory Visibility
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J